Translational Development Acquisition Corp.

Translational Development Acquisition Corp. (Nasdaq: TDAC) is a blank-check company focused on the life sciences and healthcare sector, targeting opportunities in translational medicine and biomedical development. The SPAC filed a Form 425 communication with the SEC on June 29, 2026, indicating it is actively engaged in a business combination transaction. Form 425 filings are required disclosures made in connection with proposed mergers or acquisitions, signaling that TDAC has entered a definitive stage in its deal process. The vehicle targets companies bridging early-stage scientific research and commercial healthcare applications. Visit SpacDesk and sign up for a full data subscription to access complete filing history, deal timelines, and analytics on TDAC and hundreds of other active SPACs.